Nabilone
Primary Progressive Aphasia
Simon Ducharme, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Primary Progressive Aphasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLORTAUCIPIR Mayo Clinic | Phase 4 | BBB |
Rotigotine I.R.C.C.S. Fondazione Santa Lucia | Phase 2 | B |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
FLORTAUCIPIR Mayo Clinic | Phase 1 | CC |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Nabilone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →